GO
Loading...

Novartis AG

More

  • March 4- Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching. It affects between 9 and 30 percent of the U.S. population, according to the National Institutes of Health. The company regained the U.S. and Canada rights for its schizophrenia drug Fanapt from Novartis AG late last year.

  • *Sonova buy Germany's Hansaton Akustik. ZURICH, March 2- Sonova, the world's largest maker of hearing aids, will shift jobs out of Switzerland and freeze pay for Swiss staff as it cuts costs to cope with a surge in the value of the franc. Sonova said on Monday that 100 jobs would be lost in Switzerland, with some manufacturing roles shifted to China and client services...

  • Early movers: BRK.B, AAPL, LL, CAH, BSX & more Monday, 2 Mar 2015 | 7:50 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, March 2- GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis.

  • Feb 25- Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported. Pharmacyclics could fetch $17 billion- $18 billion from a possible sale, Bloomberg said on Wednesday, citing people familiar with the matter. A Pharmacyclics official said the company does not comment on rumors or...

  • Feb 25- Cancer drugmaker Pharmacyclics Inc is exploring a possible sale of the company and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported, citing people familiar the matter. Pharmacyclics could fetch $17- $18 billion from a possible sale, Bloomberg said on Wednesday. Sales of Imbruvica, which got U.S. Food& Drug Administration...

  • Feb 23- The U.S. Food and Drug Administration on Monday approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended against approval. Farydak was approved for use in combination with Takeda Pharmaceutical Co Ltd's Velcade and...

  • Novartis' blood cancer drug wins U.S. approval Monday, 23 Feb 2015 | 3:18 PM ET

    Feb 23- The U.S. Food and Drug Administration approved Novartis AG's drug for treating a form of cancer that affects white blood cells. Multiple myeloma causes these cells to rapidly multiply and crowd out healthy blood cells from the bone marrow. The drug, Farydak, slows the multiplication of cells or causes them to die by blocking the activity of certain enzymes...

  • WASHINGTON, Feb 23- Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs, with conditions, the U.S. Federal Trade Commission said on Monday. The deal is one of three related transactions announced in April 2014 in which GlaxoSmithKline would buy Novartis' global vaccine business, except for flu vaccines, Novartis would buy Glaxo's...

  • Does this biotech stock have more upside? Thursday, 19 Feb 2015 | 5:57 PM ET
    Lab technician injecting liquid into a microtiter plate

    Receptos CEO Faheem Hasnain told CNBC that "there's only one strategy to run a business."

  • Dallas home prices surge on short supply Thursday, 19 Feb 2015 | 11:25 AM ET
    Dallas Texas

    The median price of a Dallas home was 12.3 percent higher in December 2014 than it was a year earlier, more than twice the national average.

  • LONDON, Feb 17- Bonds issued by European blue chips such as EDF, Nestle and Royal Dutch Shell have slipped into negative-yield territory as investors seek refuge from sub-zero central bank rates. The European Central Bank's monetary easing measures- including a deposit rate at -0.2 percent and a pledge to buy 1 trillion euros of bonds- have turned bond markets on...

  • WASHINGTON, Feb 10- For the first time in 20 years, patients suffering from the eye disease glaucoma may soon have new treatments as several young companies look to shake up the $5.6 billion global market. No new class of medicine has been introduced since Pfizer Inc's N> Xalatan, known generically as latanoprost, in 1996.. The newcomers aim to disrupt...

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.

  • Feb 5- Drugmaker Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectible drugs and biosimilars, or copies of biotech drugs. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira soared 35 percent to near $88 before the bell Thursday, while Pfizer was up 3.6...

  • GSK sales falls; firm upbeat on respiratory unit Wednesday, 4 Feb 2015 | 8:45 AM ET

    Shares of GlaxoSmithKline jumped on Wednesday, despite the company posting a 3 percent fall in full-year revenue.

  • *Novartis deal on track to close in first half 2015. GSK is also banking on an asset swap with Novartis to help revive its fortunes, and looking to unlock value by floating its HIV unit ViiV Healthcare. GSK is buying vaccines, selling cancer drugs and forming a consumer health joint venture with Novartis in a $20- billion transaction designed to ensure more stable...

  • LONDON, Feb 4- GlaxoSmithKline said on Wednesday it expected to start to regain market share in respiratory medicine after weak demand for lung drug Advair again hurt fourth-quarter sales, capping a rough year for Britain's top drugmaker. GSK is also banking on an asset swap with Novartis to help revive its fortunes, and looking to unlock value by floating its...

  • CHICAGO, Feb 4- After successfully treating four Ebola patients last year, Emory University in Atlanta is now leading a government-funded project that will use blood from survivors of the deadly virus to test a novel way of treating infectious disease. The Defense Advanced Research Projects Agency, the Pentagon's elite research arm, has awarded Emory up to...

  • *Novartis: received pre-notification from health ministry. *Novartis says financial impact would be manageable. ZURICH, Feb 3- Swiss drugmaker Novartis said on Tuesday its Japanese business faced suspension by the country's health ministry but that it could manage the financial impact of such a sanction.